EVIDENCE PROFILE / PUBLISHED
B7-33
B7-33 is a synthetic single-chain analogue of the human relaxin-2 B-chain, distinct from relaxin-2 and from serelaxin. No human administration study was identified in the sources reviewed, and no Canadian approved product was found; the evidence is rodent and cell-based.
Evidence at a glance
- Human
- None foundNo human administration study located; only in-vitro human cell assays in the sources reviewed.
- Animal/cell
- LimitedOne originating rodent and cell study, plus a later cell-assay-only follow-up from the same group.
- Approved medicine
- None foundThree Health Canada drug database ingredient queries, each with no matching records.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. This concise profile was researched from primary and regulatory records; supplier listings were used only to find the name.
Identity
B7-33 is a synthetic single-chain analogue derived from the B-chain of human relaxin-2 (H2 relaxin), described by its originating group as B-chain residues 7-29 with a C-terminal KRSL extension taken from positions 30-33 of the B1-33 isoform. The originating paper also describes replacing the two B-chain cysteines at positions 11 and 23 with isosteric serine residues, which it reports prevented dimerisation and aggregation and left a freely water-soluble, positively charged single-chain peptide. It is not relaxin-2 itself and not serelaxin, the recombinant two-chain hormone. Neither reviewed paper prints a full residue-by-residue sequence in its body text; the sequence appears only in a figure and in supplementary material. The catalogue material's identity, purity and formulation are unverified.
Biological mechanism or research interest
Research interest comes from RXFP1 signalling: in the 2016 originating study B7-33 bound RXFP1, raised MMP-2 in human cardiac fibroblasts and rat renal myofibroblasts, and potently activated pERK1/2 in the rat renal myofibroblasts, while in HEK-293T cells overexpressing human RXFP1 it induced pERK1/2 poorly and acted as a full but weak cAMP agonist. Drawing these results together, the authors described it as the first reported functionally selective agonist of that receptor; no cAMP measurements in fibroblasts are reported, so the pathway preference is their interpretation rather than a direct within-cell comparison. Later work from the same group has centred on shortening or stabilising the peptide.
Verified approved human uses
No approved human use was verified in the sources reviewed. Health Canada Drug Product Database active-ingredient searches performed on 2026-10-27 returned 0 records for "b7-33", 0 records for "relaxin" and 0 records for "serelaxin". An absence of records under those names in one jurisdiction's database is not a worldwide regulatory review, and it says nothing about the quality of any research material. Regulatory or clinical history belonging to the parent hormone relaxin-2, to serelaxin or to later derivative analogues does not transfer to B7-33.
Investigational human evidence
No human administration study of B7-33 was identified in the sources reviewed. The 2016 originating paper reports no human administration and uses human cardiac fibroblasts in vitro only, and the 2023 follow-up from the same group reports peptide synthesis, receptor-binding and cAMP assays in HEK cells and circular dichroism, with no animal or human experiments and an institutional-review statement of "not applicable". Human pharmacokinetics, tolerability and clinical outcomes are therefore unaddressed by the two papers reviewed here.
Popular claims versus demonstrated findings
Descriptions of B7-33 as an anti-fibrotic or heart- and lung-repair agent rest on rodent and cell data, not on human outcomes. The originating paper itself reports markedly lower RXFP1 binding affinity and lower cAMP potency than H2 relaxin in HEK cells expressing human RXFP1. Results for H2 relaxin, for serelaxin or for the truncated, Aib-substituted and hydrocarbon-stapled analogues made in 2023 do not transfer to B7-33; in that paper a two-residue C-terminal truncation (B7-31) was tolerated, while further truncation, every Aib substitution tried and rigid hydrocarbon stapling each reduced binding rather than improving it.
Human versus animal or cell evidence
The 2016 study reports increased MMP-2 in human cardiac fibroblasts and rat renal myofibroblasts, reduced left-ventricular collagen and reduced end-diastolic pressure in a rat post-myocardial-infarction model, reduced cardiac collagen in an isoproterenol-treated mouse model, and reversal of airway epithelial thickening with normalised lung collagen in an ovalbumin mouse allergic-airways model treated intranasally; and, in an orthotopic RM1 prostate tumour model in male C57BL/6J mice, it did not increase prostate tumour size relative to body weight, whereas H2 relaxin increased it by more than 150%. These are animal and cell findings only, from a single originating group.
Limitations and known risks
Human pharmacokinetics, immunogenicity, impurity profile and route-specific safety are not characterised in the sources reviewed. The originating authors report the peptide as largely unstructured in solution with weak RXFP1 binding and describe it as a lead for further modification to improve stability and potency; the 2023 study found that truncation beyond a tolerated two-residue C-terminal shortening, Aib substitution and rigid hydrocarbon stapling each reduced binding. Mechanistic conclusions about RXFP1 and AT2 receptor involvement were inferred from antagonist experiments. The 2016 paper carries no competing-interest or patent statement, although two of its authors are the inventors named on the patent disclosed in the 2023 paper.
